By screening compounds which inhibit the cell-surface expression of MHCclass II molecules, we found that concanamycin B inhibits the expression of functional MHC class II molecules and suppresses the antigen presentation by this molecule. MHCclass II molecules play a role of self/non-self discrimination in the immune system and are also involved in the development of autoimmune diseases6~10). MHCclass II molecules typically assemble in the ER as a stoichiometric complex with a nonpolymorphic invariant chain (Ii), a type II JUNE 1995 integral membraneprotein. This complex is transported out of ER and through the Golgi, undergoing terminal glycosylation during this passage. The MHCclass Il-Ii complexes then appear to move to lysosome-related compartments. In these compartments the Ii chain is removed from MHCclass II molecules by proteases and the peptide antigen processed in the lysosome then binds to the MHCclass II molecule. This peptide-bearing dimer transits to the cell surface and stimulates helper T cells.
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Since acidotropic agents such as chloroquine (CQ) or ammonium chloride inhibit antigen presentation by MHCclass II molecules, acidification in organelles is critical for antigen presentation by"these molecules1 1' 1 2).
Weshowhere that concanamycin B is a more potent and specific inhibitor of the antigen presentation by MHC class II molecules. (C) Non-macrocyclic product
Materials and Methods
To an ice-cooling solution of concanamycin B (4mg) in dry MeOH (0.2ml) was added <i/-10-camphorsulfonic acid (CSA) (0.2 mg). After stirring at 25°C for 30 minutes, the mixture was neutralized with amberlite IRA-400 resin and filtered. The filtrate was concentrated to a crude product which was chromatographed on silica gel with 1 : 4 benzene -ethyl acetate to afford 0-methylconcana- EDTA, leupeptin (5 /zg/ml) and pepstatin A (5 /xg/ml).
After homogenization, the suspension was centrifuged at 1,000 x g for 7minutes and the supernatant was again centrifuged at 200,000 x g for 30 minutes. The pellets were washed once and suspended in the same buffer. ATP-dependent H +-transport in the absence or presence of concanamycin B was assayed by measuring the fluorescence quenching of acridine orange in 20 mMMOPSTris (pH 7.0) buffer containing 0.2m sucrose, 0.1 m KC1, 2 mMMgCl2, 1 mMvalinomycin and 5 mMacridineorange (2ml). 5 nMconcanamycin B was added after and before the addition of Mg-ATP. The activity was sensitive to l mMAf-ethylmaleimide and 50nM bafilomycin Al but insensitive to 5 /xg/ml of oligomycin, 5 mMazide, or 1 mM vanadate. Synaptic vesicles were prepared from rat brain by previously described methods14'1 5*. ATP-dependent 489 H + -transport in the absence or presence ofconcanamycin B was assayed as above.
Cells and Culture Conditions
The lymphocytes from spleen or lymph node were centrifuged through lympholyte-M (Cedarlane Co.) and washed three times in RPMI-1640 medium, and used for the experiments. A native goat immimoglobulin (NGG) specific T cell clone, 52-2D, was established from BALB/c mice immunized with NGG. Colo 205 adenocarcinoma cells, WEHI-3 cells, and A20-2JB lymphoma cells were cultured in RPMI-1640 supplemented with 10% FCS, 5 x 10~5 m 2-mercaptoethanol, 100/ig/ml glutamine, 100 u/ml penicillin, and lOO u/ml streptomycin. (Fig. 1-A) . By utilizing this system, we screened the natural chemical compounds which specifically inhibited the MHCclass II expression. As shown in Fig. 1-A, concanamycin B (50 nM) selectively suppressed the induction of MHCclass II molecules, whereas it did not affect the expression of MHCclass I and ICAM-1 molecules (Fig. 1-A) . We also examined the effect of concanamycin B treatment on the MHC class II expression on mousemyelomonocyteWEHI-3 and mouse splenic cells. As shown in Fig. 1-B ( Fig. 1-B ).
Since both CQ and brefeldin A (BFA) have been demonstrated to suppress cell-surface expression of MHCclass II molecules16'1 7), therefore, we investigated the effect of CQ and BFAon the induction of MHC class I, MHCclass II and ICAM-1molecules on Colo 205 cells. BFA, which blocks the egress of proteins from ER, completely suppressed the expression of these cell-surface glycoproteins ( Fig. 1-A) . Since 50jllm CQ partially suppressed the expression of MHCclass II molecules without influencing MHCclass I and ICAM-1 expression, we increased the concentration of CQ" to 200 /iM to completely inhibit the expression of MHCclass II molecules. However, under this condition it also abrogated the expression of MHCclass I and ICAM-1 molecules ( Fig. 1-A) . These results suggest that concanamycin B is more potent and allows a more specific inhibition of MHCclass II expression than CQor BFA. which incorporates a six membered hemiketal ring with a 3-carbamate derivative of 2-deoxy-jS-D-rhamnose moiety ( Fig. 3-a) . Removal of the sugar moiety increased the inhibitory effect on both V-ATPaseand MHCclass II expression, suggesting the /?-D-rhamnose structure to be dispensable for both biological activities (Fig. 3 , Table  1 ). Although alkaline degradation decreased both types of activity, this transformation is not critical. However, hydride reduction of the 1 8-memberedlactone completely destroyed its inhibitory activities for both V-ATPase activity and MHCclass II expression (Fig. 3 , Table 1 ).
Therefore, the 18-membered macrolide structure in concanamycin B is critical for both biological activities. (Fig. 4) . Concanamycin B, therefore, blocks MHC class II expression post-transcriptionally.
Concanamycin B Inhibits Antigen Presentation
by MHCClass II Molecules Since it has recently been shown that physiologically processed products derived from exogenous antigens We used cyclosporin A for control experiment25'26).
Cyclosporin A inhibits the production of IL-2 without the influence on T cell proliferation. However, concanamycin B did not affect the production of IL-2 even if it inhibits the proliferation of T cells (Fig. 5-A) . These data eliminate the possibility that concanamycin B has some effect on antigen-induced IL-2 production by T cells. Therefore, weexaminedthe antigen presentation by measuring the IL-2 production after T cells were cultured with antigen presenting cells. As shown in Fig.  5 -B, antigen presentation was carried out in an antigen- In addition, concanamycin B may also inhibit the degradation of exogenous antigens in the endosomes and lysosomes by elevating the pH, because an acidic pH 3~4 is necessary for optimal activity of the proteases involved in degradation.
As described above, concanamycin B obstructs the dissociation of the Ii chain from the MHC class II molecules. As a result the Ii chain which is still associated with the MHCclass II molecules might interfere with proper binding of a peptide. 493 However,even if the antigenic peptides are able to bind to this immature Ii-MHC class II molecule the antigen probably still can not be presented due to the decreased ability of the complex to be transported to the cell surface or T cells can not recognize the antigen presented by the immature Ii-MHC class II complex.
